Adjuvant therapy for cutaneous melanoma: a systematic review and network meta‐analysis of new therapies
- 12 November 2019
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 34 (5) , 956-966
Abstract
New drugs have been recently approved as adjuvant therapies for melanoma. In this Bayesian network meta‐analysis, we aimed to assess the best therapeutic option in terms of recurrence‐free survival (RFS), overall survival (OS) and adverse events (AEs). PubMed, Embase, Cochrane library and the American Society of Clinical Oncology databases were searched from inception until 20 August 2018. We estimated adjusted hazard ratios (HRs) for RFS and OS and relative odds ratios (ORs) for AEs and surface under the cumulative ranking (SUCRA) probabilities were calculated. A number of 872 records were identified, and six were finally included in the meta‐analysis. A total of 4244 patients in six studies were randomized. The following therapies were considered in the selected studies: combined dabrafenib and trametinib, vemurafenib, nivolumab, ipilimumab and pembrolizumab. Nivolumab demonstrated the highest probability (75.1%) of being the best in term of RFS, followed by dabrafenib+trametinib, pembrolizumab, ipilimumab and vemurafenib; however, OS was not estimable. Concerning AEs, pembrolizumab and nivolumab showed the highest probability to be less associated with any and 3–4 grade AEs (83.1% and 64.4%, respectively). In conclusion, all new drugs are highly effective in adjuvant setting, and the best choice is dependent of patient's context.Keywords
This publication has 17 references indexed in Scilit:
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017
- Survival of patients with advanced metastatic melanoma: the impact of novel therapies–update 2017European Journal of Cancer, 2017
- Adjuvant Therapy for MelanomaCurrent Oncology Reports, 2017
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant TherapyNew England Journal of Medicine, 2016
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trialThe Lancet Oncology, 2015
- Graphical Tools for Network Meta-Analysis in STATAPLOS ONE, 2013
- Clinical characteristics and outcomes with specific BRAF and NRAS mutations in patients with metastatic melanomaCancer, 2013
- Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysisJNCI: Journal of the National Cancer Institute, 2010
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trialsCancer Treatment Reviews, 2003